ABSTRACT
BACKGROUND: Therapeutic targets supported by genetic evidence from genome-wide association studies (GWAS) show higher probability of success in clinical trials. GWAS is a powerful approach to identify links between genetic variants and phenotypic variation; however, identifying the genes driving associations identified in GWAS remains challenging. Integration of molecular quantitative trait loci (molQTL) such as expression QTL (eQTL) using mendelian randomization (MR) and colocalization analyses can help with the identification of causal genes. Careful interpretation remains warranted because eQTL can affect the expression of multiple genes within the same locus. METHODS: We used a combination of genomic features that include variant annotation, activity-by-contact maps, MR, and colocalization with molQTL to prioritize causal genes across 4,611 disease GWAS and meta-analyses from biobank studies, namely FinnGen, Estonian Biobank and UK Biobank. RESULTS: Genes identified using this approach are enriched for gold standard causal genes and capture known biological links between disease genetics and biology. In addition, we find that eQTLs colocalizing with GWAS are statistically enriched for corresponding disease-relevant tissues. We show that predicted directionality from MR is generally consistent with matched drug mechanism of actions (>78% for approved drugs). Compared to the nearest gene mapping method our approach also shows a higher enrichment in approved therapeutic targets (risk ratio 1.38 vs 2.06). Finally, using this approach, we detected a novel association between the IL6 receptor signal transduction gene IL6ST and polymyalgia rheumatica, an indication for which sarilumab, a monoclonal antibody against IL-6, has been recently approved. CONCLUSIONS: Combining variant annotation and activity-by-contact maps to molQTL increases performance to identify causal genes, while informing on directionality which can be translated to successful target identification and drug development.
Competing Interest Statement
SL, MC, MB, SS, CC, EdR, KK, JS, SK are employees of Sanofi US Services and hold shares and/or stock options in the company. DKR is currently an employee of Takeda and was an employee of Sanofi US Services at the time of study. All authors declare no other competing interests.
Funding Statement
This study was funded by Sanofi (Cambridge, MA, United States). The funder had the following involvement with the study: Sanofi reviewed the manuscript. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, and Novartis AG. UK Biobank is supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest Regional Development Agency, British Heart Foundation and Cancer Research UK. Estonian Biobank research was supported by the European Union through Horizon 2020 research and innovation programme under grant no 810645 and through the European Regional Development Fund project no. MOBEC008, by the Estonian Research Council grant PUT (PRG1291, PRG687 and PRG184) and by the European Union through the European Regional Development Fund project no. MOBERA21 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 and Project No. 2014-2020.4.01.16-0125.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20). The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 6 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001. UK Biobank has received ethical approval from the NHS National Research Ethics Service North West (approval numbers 11/NW/0382 and 16/NW/0274). All participants provided written informed consent. Estonian Biobank GWAS and consecutive meta-analyses were carried out under ethical approval permit number 1.1-12/1020 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs). Other datasets used were publicly available.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The UK Biobank Pan ancestry GWAS[45] are available through https://pan.ukbb.broadinstitute.org/. FinnGen GWAS are available through https://www.finngen.fi/en/access_results. Processed and formatted eQTL data used in this study are available through the eQTL catalogue https://www.ebi.ac.uk/eqtl/. pQTL from Sun et al. 2018 are available through http://www.phpc.cam.ac.uk/ceu/proteins/. eQTLGen eQTL are available through https://www.eqtlgen.org/phase1.html. 1000 Genomes project phase 3 data is available through https://www.internationalgenome.org/category/phase-3/. Activity-by-contact maps are available through https://www.engreitzlab.org/resources/. LoGoFunc gain and loss of function predictions are available through https://itanlab.shinyapps.io/goflof/. Datasets supporting the conclusions of this article are included within the article and its additional files. Additional datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
https://pan.ukbb.broadinstitute.org/
https://www.finngen.fi/en/access_results
http://www.phpc.cam.ac.uk/ceu/proteins/
https://www.eqtlgen.org/phase1.html
https://www.internationalgenome.org/category/phase-3/
